Effectiveness of Paclitaxel-coated Luminor® Balloon Catheter Versus Uncoated Balloon Catheter in the Arteria Femoralis Superficialis

Jena University Hospital172 enrolled

Overview

The aim of this clinical trial is to evaluate the safety and efficacy of the novel Luminor® paclitaxel drug-eluting balloon (iVascular, S.L.U., Barcelona, Spain) in inhibiting restenosis and in ensuring long-term patency.

The investigational medical device represents the Paclitaxel drug-eluting Luminor®-35 balloon catheter which is based on a proprietary transfertech coating technology. This has been engineered to improve clinical efficacy by optimizing coating properties and device functionalities. This allows a homogeneous and precise Paclitaxel concentration of 3 μg/mm2 on the PTA balloon surface. The balloon dilatation procedure, including deployment to the target lesion and balloon inflation, deflation and retrieval, is performed under fluoroscopic observation. All sites shall have access to an emergency unit to perform also interventions as bypass surgery e.g. in case of failed percutaneous transluminal angioplasty (PTA). The patient is positioned on the angiographic table and draped in a sterile fashion. The standard vascular access represents the ipsilateral or contralateral femoral artery in accordance to the target vessel. The endovascular procedure can be performed in a direct antegrade or a cross-over retrograde technique. An introducer sheath will be inserted over a guidewire. 5.000 I.U. heparin is injected i.a. to pre-vent peri-procedural thrombotic events. Alternative peri-procedural anti-coagulation regimens may be applied if justified by individual patient requirements. An endoluminal guidewire passage of the stenotic and occlusive femoro-popliteal lesion is mandatory for study inclusion. A POBA PTA balloon of appropriate balloon diameter and length, and catheter working length is selected according to the characteristics of the target vessel and lesion for the pre-dilation and assessed by angiography (DSA or XA). A ruler has to be adjacent to the target vessel. After pre-dilatation of the target lesion an angiographic assessment will be performed (DSA or XA). A ruler has to be adjacent to the target vessel. Randomization will be performed by envelope pull. The treatment group represents the Lumi-nor® DEB and the control group POBA applying a CE-marked non-drug-eluting PTA balloon catheter. In patients with peripheral artery disease, quantitative vascular angiography (QVA) is essential for the analysis of the degree of the arterial stenosis. For quantitative assessment of stenotic lesions, the residual lumen at the lesion site is compared with the lumen at a reference site. QVA will be assessed by an independent core lab. The assessment during the angioplasty is performed pre- and post-procedure, at 6 months follow-up and any unscheduled procedure if necessary. Follow-up (FU) assessments will occur at pre-discharge, 6, 12 and 24 months following the study procedure.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

172

Conditions

Peripheral Arterial Disease

Interventions

Transluminal Angioplasty with Paclitaxel-coated Luminor® Balloon Catheter in the Superficial Femoral and Popliteal ArteriesDEVICE

Endoluminal guidewire passage of the stenotic and occlusive femoro-popliteal lesion must be performed. A pre-dilatation follows. Then the investigational procedure (DEB) is assigned by randomization. Luminor35®-DEB PTA catheter is applied.

Transluminal Angioplasty with and non-coated (CE-marked) plain old angioplasty balloon (POBA) catheterDEVICE

Endoluminal guidewire passage of the stenotic and occlusive femoro-popliteal lesion must be performed. A pre-dilatation follows. Then the investigational procedure is assigned by randomization. POBA catheter is applied.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Age ≥18 years 2. Subject must agree to undergo the 6-month angiographic and clinical follow-up (at 12 month post-procedure) 3. Peripheral vascular disease Rutherford class 2-4 4. De novo stenotic/re-stenotic lesion or occlusive lesions in the superficial femoral (SFA) and/or popliteal arteries (PA) 5. If the index lesion is re-stenotic, the prior PTA must have been \>30 days prior to treatment in the current study 6. ≥70% diameter stenosis or occlusion 7. Target lesion length: ≤15 cm (TASC II A and B) 8. Only one lesion per limb and per patient can be treated (see definition chapter 6.5) 9. ≥ one patent intrapopliteal run-off artery to the foot of the index limb 10. Successful endoluminal guidewire passage through the target lesion 11. Predilatation prior to randomization 12. Life expectancy, in the investigators opinion of at least one year 13. Subject is able to verbally acknowledge and understand the aim of this trial and is willing and able to provide informed consent Exclusion Criteria: 1. Previous surgery in the target vessel 2. Major amputation in the same limb as the target lesion 3. Presence of aneurysm in the target vessel 4. Acute myocardial infarction within 30 days before intervention 5. Severely calcified target lesions in the SFA/PA resistant to PTA 6. Subjects requiring different treatment or raising serious safety concern regarding the procedure or the required medication 7. Women of childbearing potential expect women with the following criteria: * post-menopausal (12 month natural amenorrhea or 6 month amenorrhea with serum FSH \> 40mlU/ml) * sterilization 86 weeks after bilateral ovariectomy with or without hysterectomy * using an effective method of birth control for the duration of the trial: implants, injectables, combined oral contraceptives, intrauterine device (in place for a period of at least 2 months prior to screening) and with negative serum pregnancy test * sexual abstinence * vasectomy partner 8. Pregnant and nursing women 9. Acute thrombus, stent or aneurysm in the index limb or vessel 10. Renal insufficiency with a serum creatinine \>2.0 mg/dL at baseline 11. Platelet count \<50 G/l or \>600 G/l at baseline 12. Known hypersensitivity or contraindication to contrast agent that cannot be adequately pre-medicated 13. Subjects with known allergies against Paclitaxel 14. Subjects with intolerance to antiplatelet, anticoagulant, or thrombolytic medications that would be administered during the trial 15. Dialysis or immunosuppressant therapy 16. Current participation (or within the last 3 months) in another interventional study

Locations (11)

Herzzentrum Bad Krozingen

Bad Krozingen, Baden-Wurttemberg, Germany

SRH Klinikum Karlsbad-Langensteinbach

Karlsbad-Langensteinbach, Baden-Wurttemberg, Germany

Institut für Klinische Radiologie, Klinikum der Ludwig Maximilians Universität München - Campus Innenstadt

München, Bavaria, Germany

Outcomes

Primary Outcomes

Change in Late Lumen Loss (LLL)

Change in Late Lumen Loss (LLL), defined as difference between the diameters (in mm) at 6 months follow-up minus post-procedure.

Time frame: at baseline and after 6 months